Physician profile
Cherian John
NPI 1891792099
$14,440.61
in general payments reported to CMS, 2019-2025
54 companies · $2,195 in 2025
The $2,195 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,495 · 2020: $1,533 · 2021: $1,349 · 2022: $2,502 · 2023: $2,093 · 2024: $2,274 · 2025: $2,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,472 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,472.43 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,877.99 | 2019-2025 | Farxiga, Brilinta, Airsupra |
| Pfizer INC. | $869.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $862.45 | 2019-2025 | |
| Amgen INC. | $829.22 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Novo Nordisk INC | $812.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $671.60 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $646.19 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $629.07 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $595.48 | 2023-2024 | Inpefa |
| Lundbeck LLC | $592.47 | 2019-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.12 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $520.03 | 2020-2025 | Verquvo |
| Zoll Respicardia, INC. | $499.68 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $466.60 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $406.38 | 2019-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $343.49 | 2019-2024 | Mounjaro |
| Amarin Pharma, INC. | $306.56 | 2019-2023 | |
| Mylan Specialty L.P. | $290.82 | 2022-2024 | Yupelri |
| Glaxosmithkline, LLC. | $281.21 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Corcept Therapeutics | $219.74 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.18 | 2019-2025 | Xifaxan |
| Viatris Specialty LLC | $171.93 | 2025 | Yupelri |
| Irhythm Technologies, INC. | $160.73 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Exact Sciences Corporation | $150.80 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Actelion Pharmaceuticals US, INC. | $128.50 | 2019-2025 | Opsynvi, Uptravi |
| Bridgebio Pharma, INC. | $116.22 | 2025 | Attruby |
| Daiichi Sankyo INC. | $115.99 | 2021-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $110.11 | 2019-2020 | |
| Abbvie INC. | $109.88 | 2023-2024 | |
| Celgene Corporation | $83.74 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $79.89 | 2025 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $79.62 | 2019 | |
| Medtronic Vascular, INC. | $69.35 | 2019 | |
| Abbott Laboratories | $69.25 | 2021-2025 | Confirm Rx |
| Heartflow, INC. | $60.68 | 2025 | |
| Sunovion Pharmaceuticals INC. | $53.62 | 2019 | |
| Edwards Lifesciences Corporation | $45.52 | 2023 | |
| Astellas Pharma US INC | $41.58 | 2020 | |
| Gilead Sciences, INC. | $40.41 | 2019 | |
| Cvrx, INC. | $40.33 | 2024 | Barostim Neo System |
| Boston Scientific Corporation | $39.12 | 2023-2024 | Watchman Access System |
| Kerecis Limited | $25.98 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Portola Pharmaceuticals, LLC | $24.92 | 2019 | |
| Phathom Pharmaceuticals, INC. | $24.22 | 2024 | Voquezna |
| Acorda Therapeutics, INC | $22.11 | 2019 | |
| Paratek Pharmaceuticals, INC. | $20.19 | 2023 | Nuzyra |
| Verona Pharma, INC. | $18.62 | 2025 | Ohtuvayre |
| Acadia Pharmaceuticals INC | $16.74 | 2024 | Nuplazid |
| Azurity Pharmaceuticals, INC. | $15.19 | 2024 | Edarbi |
| Kiniksa Pharmaceuticals International, Plc | $14.92 | 2024 | Arcalyst |
| Amneal Pharmaceuticals LLC | $12.31 | 2019 | |
| Bard Peripheral Vascular, INC. | $11.98 | 2021 | |
| Eisai INC. | $11.57 | 2021 | |
| United Therapeutics Corporation | $5.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherian John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.